China's First Autologous NK Cell Therapy Covering Eight Tumor Indications Approved for Clinical Use at West China Lecheng Hospital in Boao, Priced at RMB 49,800 per Infusion

Recently,The first in China to cover eight types of tumor indicationsAutologous NK Cell Adjuvant Therapy TechnologyOfficially approved for clinical application at Huaxi Licheng Hospital.

It is reported that the cost of a single treatment of this therapy is 49,800 yuan, with a total of 6 treatments per course, and the total cost of the entire course is approximately 298,800 yuan. It covers eight types of tumor indications: lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer, liver cancer, prostate cancer, and colorectal cancer.

It can be said that the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Free Trade Port has recently ushered in another breakthrough in the field of cell therapy, with a group of biomedical new technologies at internationally advanced levels successively approved and entering a new phase of clinical transformation and application.

On January 20, Shulan (Boao) Hospital announced that,Autologous NK Cell Therapy Technology"Officially approved for clinical application at the hospital.

Recently, the "Type 2 Diabetes Treatment Technology Using Human Umbilical Cord Mesenchymal Stem Cells"Has also been approved by the Lecheng Medical Drug Administration, applicable to patients whose blood sugar remains poorly controlled after using at least three hypoglycemic drugs (including insulin) in combination."

Not long ago, Hengsai Biotech'sKSD-101 Dendritic Cell (DC) Drug——Biomedical New Technology for Treating EBV-related Hematological Tumors—— officially landed at Hainan Hospital of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

In addition,On January 10, 2026, Boao Super Hospital announced, "German DC Immunocyte Therapy Technology"Approved for clinical application in the hospital.

In addition to the aforementioned newly approved projects, 15 cell and gene therapy technologies have already been implemented in the Lecheng Pilot Zone:

(1) Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Knee Osteoarthritis: Price 36,000 RMB per treatment,Landed at Ruijin Hospital。

(2) Stem cell therapy technology for the basal layer of airways in chronic obstructive pulmonary disease: Price 150,000 RMB per treatment,Landed at Ruijin Hospital。

(3) Periodontal Disease Treatment Technology Using Dental Pulp Mesenchymal Stem Cells: Treatment cost for a single tooth is 59,800 RMB, implemented at Yiling Hospital.

(4) Stem cell therapy for basal layer of airway in bronchiectasis: Price 150,000 RMB per treatment, implemented at Ruijin Hospital.

(5) Human umbilical cord mesenchymal stem cell (VUM02 injection) treatment for liver cirrhosis: One course of treatment costs 450,000 yuan, implemented by Meisai'er Hospital.

(6) Airway basal layer stem cell therapy technology for interstitial lung disease: Price 150,000 RMB/time,Landed at Ruijin Hospital。

(7) Umbilical Cord Mesenchymal Stem Cell Therapy for Early-Onset Ovarian Insufficiency: Price 80,000 RMB per session, available at Ciming Hospital.

(8) Gene therapy for inherited retinal dystrophy associated with biallelic RPE65 mutations: Price 480,000 RMB/monocular,Landed at Ruijin Hospital。

(9) Improvement of Mesenchymal Stem Cell Therapy Derived from Human Umbilical Cord for Heart Failure with Reduced Ejection Fraction: Price 60,000 RMB per treatment,Landed at Huaxi Hospital。

(10) Menstrual Blood Mesenchymal Stem Cell Therapy for Pulmonary Fibrosis: Price 1.4 million RMB per course, available at Shulan Hospital.

(11) Mesenchymal stem cell therapy for alleviating complications after bone marrow transplantation: Price 80,000 RMB/bottle, implemented at Huaxi Hospital.

(12) Personalized DC Vaccine Treatment Technology for Malignant Tumors: Price 150,000 RMB per injection,Landed at Huaxi Hospital.

(13) Cellular vaccine therapy against EB virus infection: Price 16,000 RMB per treatment,Landed at Huaxi Hospital.

(14) Activated T Lymphocyte Therapy for Preventing Postoperative Recurrence of Liver Cancer:Price: 100,000 RMB/time, implemented at Shulan Hospital.

(15) Human umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis:Price: 50,000 RMB/time, provided by Huaxi Hospital.

Statement:In ChinaVolumeDerived from official announcements,Cell and Gene Therapy Field Official Accountetc.Place, this publicPublic PlatformAiming at knowledge sharing, maintaining neutrality towards the content, statements, and viewpoints of reprinted or shared materials, without guaranteeing their accuracy.Accuracy, reliability, or completeness, no express or implied warranty is made, and the relevant content is for reference only.